Acquired Long QT Syndrome
Camm, A. John (Auteur) / Malik, Marek (Collaborateur) / Yap, Yee Guan (Collaborateur)
Blackwell futura;Blackwell Publishers
2004
vi, 199 pages : illustrations.
Comprend un feuillet d'accompagnement.
Comprend un index.
9781405118385;1405118385
Anglais
1. Introduction -- 2. Mechanisms of acquired QT prolongation and torsades de pointes -- 3. Measurement of the QT interval and repolarization assesment -- 4. Introduction to drug-induced long QT syndrome -- 5. Risk of QT prolongation and torsades de pointes with antiarrhrythmic drugs -- 6. Risk of QT prologation and torsades de pointes with antihistamines -- 7. Risk of QT prolongation and torsades de pointes with psychotropic drugs -- 8. Risk of QT prolongation and torsades de pointes with antimicrobial and antimalarial drugs -- 9. Risk of QT prolongation and torsades de pointes with prokinetics and miscellaneous other drugs -- 10. Acquired long QT syndrome secondary to cardiac conditions -- 11. Acquired long QT syndrome secondary to noncardiac conditions -- 12. Perspective on drug-induced repolarization changes
In recent years there has been considerable interest in the diagnosis and understanding of ventricular repolarisation, particularly the QT interval prolongation and abnormal T and T/U wave morphology associated with torsades de pointes. Advances in ion channel cloning have greatly improved our understanding of the role of ionic channels in mediating cardiac repolarisation. Unfortunately, it is increasingly recognised that a number of drugs, both those associated with altering repolarisation, and others for non-cardiac conditions can increase the propensity for polymorphic ventricular tachycardia, syncope and even ventricular fibrillation and sudden death.
In this volume, arrhythmia specialists from St. George's Hospital Medical School, London discuss the mechanisms behind QT prolongation and torsades de pointes. They focus particularly on the risk of individual cardiac and non-cardiac drugs in provoking long QT syndrome, providing a comprehensive review which will be useful for all electrophysiologists treating polymorphic ventricular tachycardias, and will expose important regulatory issues for pharmaceutical authorities and for the wider medical community.
Médicaments - Effets secondaires / Cardiologie / Syndrome du QT long
WG 330 C184a 2004
Exemplaires
Nbre d'exemplaires : 1| N° | Cote | Localisation | |
|---|---|---|---|
| 1 | WG 330 C184a 2004 | Bibliothèque Norman-Bethune [disponible] |